SCHEMBL5477222

SCHEMBL5477222

Nc1nccc2scc(C(=O)Nc3cccc(Oc4ccccc4)c3)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.55
EGFR P00533 2/20 0.48
BTK Q06187 1/20 0.48
MAP4K4 O95819 6/20 0.48
AXL P30530 6/20 0.48
CSNK1G2 P78368 6/20 0.48
MAP4K2 Q12851 6/20 0.48
STK3 Q13188 6/20 0.48
CAMK2B Q13554 6/20 0.48
CAMK2G Q13555 6/20 0.48
CAMK2D Q13557 6/20 0.48
MINK1 Q8N4C8 6/20 0.48
HIPK4 Q8NE63 6/20 0.48
SLK Q9H2G2 6/20 0.48
CLK4 Q9HAZ1 6/20 0.48
MKNK2 Q9HBH9 6/20 0.48
LCK P06239 5/20 0.48
LYN P07948 5/20 0.48
CLK2 P49760 5/20 0.48
BLK P51451 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722710 0.90 KDR (0.59) KDRMAP4K4AXLCSNK1G2MAP4K2
SCHEMBL3529742 0.81 KDR (0.79) KDRMAP4K4AXLCSNK1G2MAP4K2
SCHEMBL5472376 0.80 KDR (0.76) KDRMAP4K4AXLCSNK1G2MAP4K2
SCHEMBL4762288 0.78 KDR (0.75) KDREGFRBTKMAP4K4AXL
SCHEMBL5468985 0.78 KDR (0.59) KDRMAP4K4AXLCSNK1G2MAP4K2
SCHEMBL1324066 0.77 KDR (0.56) KDRFLT4RETFLT1KIT
SCHEMBL2236539 0.77 CSF1R (0.49) KDREGFRBTKMAP4K4AXL
SCHEMBL5472360 0.74 KDR (0.63) KDREGFRBTKMAP4K4AXL
SCHEMBL28470212 0.73 FADS1 (0.59) KDRMEN1NPC1MAPTRAB9A
SCHEMBL4719687 0.73 MAP4K4 (0.78) KDREGFRBTKMAP4K4AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101336244-A 9-membered heterobicyclic compounds useful as protein kinase inhibitors ABBOTT LAB (US) 2008-12-31 CN disclosed
US-20070135387-A1 Inhibitors of protein kinases ABBOTT LABORATORIES 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135387-A1 Inhibitors of protein kinases MAP3K20, PACSIN2, MAP4K2 KDR 2196/4885EGFR 871/4885BTK 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.